Epigenetics Drives Pharma Innovation - Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace. - BioPharm International

ADVERTISEMENT

Epigenetics Drives Pharma Innovation
Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace.


BioPharm International
Volume 26, Issue 1, pp. 32-33

REFERENCES

1. M.E. Donohoe ME. Results Probl. Cell Differ. 55, 231–45 (2012).

2. K. Banno et al., Biochem. Res. Int. onlline, DOI :10.1155/2012/738274 738274, February, 2012.

3. Y. Boumber and J.P. Issa, Oncology 25 (3), 220–228 (2011).

4. P. Lopez-Serra and M. Esteller, Oncogene 31 (13), 1609–1622 (2012).

5. M. Esteller, N. Eng. J. Med. 358, 1148–1159 (2008).

6. P. Ao et al., Med. Hypotheses 70 (3), 678–684 (2008).

7. S.K. Bolta et al., Breast Cancer Res. Treat. 135 (3), 705–13 (2012).

8. Cai et al., Int. J. Mol. Sci. 12 (7), 4465–4487 (2012).

9. S.B. Baylin and P.A. Jones, Nat. Rev. Cancer 11 (10), 726–734 (2011).

10. M. Tessema et al., Carcinogenesis 30 (7), 1132–1138 (2009).

11. J.M Yingling JM, "The Changing Field of Drug Development," online Jul. 16, 2012. http://ecancer.org/tv/subject/611/1547/video.10 accessed Dec. 13, 2012.

12. P. Cuatrecasas, J. Clin. Invest. 116 (11), 2837–2842 (2006).

13. T. Kubota, K. Miyake, and T. Hirasawa, Clin. Epigenetics 4 (1), 1 (2012).

14. K.J. Morrow, Kalorama Reports, Pub ID: KLI3860511, pg. 160 (2012).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here